


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C07D 417/12, A61K 31/44</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/18501</b>  <b>(43) International Publication Date:</b> 29 October 1992 (29.10.92)
<b>(21) International Application Number:</b> PCT/US92/02566 <b>(22) International Filing Date:</b> 6 April 1992 (06.04.92)  <b>(30) Priority data:</b> 3/78836 11 April 1991 (11.04.91) JP  <b>(71) Applicants (for all designated States except US):</b> THE UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 541 (JP).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> SOHDA, Takashi [JP/JP]; 27-20, Higashikanmaki 2-chome, Takatsuki, Osaka 569 (JP). IKEDA, Hitoshi [JP/JP]; 13-712, 3 Nishi-Iwata 3-chome, Higashiosaka, Osaka 578 (JP). GREENFIELD, John, C. [US/US]; 6695 East E Avenue, Richland, MI 49083 (US). COLCA, Jerry, R. [US/US]; 8181 Contingo, Texas Township, MI 49009 (US). PETZOLD, Edgar, N. [US/US]; 159 South Lake Doster Drive, Plainwell, MI 49080 (US).		<b>(74) Agent:</b> WELCH, Lawrence, T.; Corporate Patents & Trademarks, The Upjohn Company, Kalamazoo, MI 49001 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

**(54) Title:** THIAZOLIDINEDIONE DERIVATIVES, PRODUCTION AND USE THEREOF**(57) Abstract**

There is disclosed a thiazolidinedione derivative of general formula (I), wherein X is -CH<sub>2</sub>- or -CO-, Q is CH<sub>3</sub>CO-, CH<sub>3</sub>CH(OR)- or -CH<sub>2</sub>COOH, when X is -CH<sub>2</sub>-, wherein R is a hydrogen atom or an acyl group, or Q is CH<sub>3</sub>CH<sub>2</sub>-, when X is -CO-, a pharmaceutically acceptable salt thereof, or a pure stereoisomeric form thereof. The thiazolidinedione derivative of general formula (I) has hypoglycemic and hypolipidemic activities.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCI\* on the front pages of pamphlets publishing international applications under the PCI\*.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TC	Togo
DK	Denmark			US	United States of America

THIAZOLIDINEDIONE DERIVATIVES, PRODUCTION AND  
USE THEREOF

FIELD OF THE INVENTION

The present invention relates to novel thiazolidinedione derivatives having hypoglycemic and hypolipidemic activities, the production thereof and a pharmaceutical composition for treating diabetes containing them.

BACKGROUND OF THE INVENTION

Various biguanide compounds and sulfonylurea compounds have been used as agents for treating diabetes. However, at present, biguanide compounds are scarcely used because they cause lactic acidosis. Although sulfonylurea compounds have strong hypoglycemic activity, they often cause serious hypoglycemia and they must be used with caution.

OBJECTS OF THE INVENTION


The present inventors have intensively studied to find out compounds having hypoglycemic activity without the above drawbacks. As a result, it has been found novel thiazolidinedione derivatives having excellent hypoglycemic and hypolipidemic activities. Thus, the present invention have been completed.

The main object of the present invention is to provide novel compounds having no above drawbacks of conventional biguanide compounds and sulfonylurea compounds.

This object as well as other objects and advantages of the present invention will become apparent to those skilled in the art from the following description.

#### SUMMARY OF THE INVENTION

According to the present invention, there is provided a thiazolidinedione derivative of the general formula (I):



wherein X is  $-\text{CH}_2-$  or  $-\text{CO}-$ , Q is  $\text{CH}_3\text{CO}-$ ,  $\text{CH}_3\text{CH}(\text{OR})-$  or  $-\text{CH}_2\text{COOH}$ , when X is  $-\text{CH}_2-$ , wherein R is a hydrogen atom or an acyl group, or Q is  $\text{CH}_3\text{CH}_2-$ , when X is  $-\text{CO}-$ , a pharmaceutically acceptable salt thereof, or a pure stereoisomeric form thereof.

The present invention also provide a pharmaceutical composition for treating diabetes comprising as an effective component the thiazolidinedione derivative of the general formula (I), a pharmacologically acceptable salt thereof or a pure stereoisomeric form thereof.

DETAILED DESCRIPTION OF THE INVENTION

Examples of the acyl group represented by R in the general formula (I) include formyl, alkylcarbonyl having 2 to 6 carbon atoms (e.g., acetyl, propionyl, isobutyryl, pentanoyl, isopentanoyl, hexanoyl, etc.), aralkylcarbonyl having 8 to 9 carbon atoms (e.g., phenylacetyl, phenylpropionyl, etc.), arylcarbonyl having 7 to 8 carbon atoms (e.g., benzoyl, p-toluoyl, etc.) and the like. The aralkylcarbonyl and arylcarbonyl may have one or more substituents such as halogen (fluorine, chlorine, bromine, etc.), lower alkoxy having 1 to 4 carbon atoms (methoxy, ethoxy, etc.), trifluoromethyl and the like.

The thiazolidinedione derivative of the general formula (I) (hereinafter referred to as the compound (I)) possesses an acidic nitrogen atom in the thiazolidine ring and a basic nitrogen atom in the pyridine ring. Therefore, the compound (I) of the present invention can exist as both its acidic and basic salts. Examples of the acidic salt include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and the like, and salts with organic acids such as methanesulfonic acid, toluenesulfonic acid, oxalic acid, malonic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, malic acid and the like. Examples of the basic salt include pharmacologically acceptable salts such as sodium salt, potassium salt, aluminium salt, magnesium

salt, calcium salt and the like.

Specific examples of the compound (I) are as follows:

5-[4-[2-(5-acetyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-acetoxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-propionyloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-butyryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-isobutyryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-valeryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-isovaleryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-pivaloyloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-[5-(1-benzoyloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione;

5-[4-[2-(5-carboxymethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; and

5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-  
2,4-thiazolidinedione.

The compound (I), the pharmacologically acceptable salt thereof, or the pure stereoisomeric form thereof has hypoglycemic and hypolipidemic activities. Further, the compound (I), the pharmacologically acceptable salt thereof or the pure stereoisomeric form thereof has low toxicity. For example, even when the compound obtained in Example 1 or 2 hereinafter was orally administered to mice in a dose of 300 mg/kg, no lethal case was observed. Therefore, the compound (I), its pharmacologically acceptable salt or pure stereoisomeric form can be used for treatment of diabetes of mammals including man as it is or by combining with a known pharmacologically acceptable carrier, excipient, filler and the like.


Normally, the compound (I), its pharmacologically acceptable salt, stereoisomeric form can be administered orally in the form of, for example, tablets, capsules including soft capsules and micro capsules, powders, granules or the like. If necessary, it can also be administered parenterally in the form of injectable solutions, suppositories, pellets or the like. In the case of oral administration, preferably, it is administered one to three times a day in a daily dose of 0.05 to 10 mg/kg.

The compound (I) and its salt of the present invention can be produced as follows.

- (1) Production of the compound (I) wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CH}(\text{OH})-$

This compound (I-1) can be produced according to the Scheme 1.

Scheme 1



wherein  $\text{R}^1$  is a hydrogen atom or a lower alkyl group, and Y is a leaving group.



Examples of the lower alkyl group represented by  $R^1$  include those having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl and the like. In particular, lower alkyl groups having 1 to 3 carbon atoms are preferred. Examples of the leaving group represented by Y include halogen atoms (e.g., chlorine, bromine, iodine), and the like.

The reaction of the compound (II) with thiourea is normally carried out in a solvent such as alcohols (e.g., methanol, ethanol, propanol, 2-propanol, butanol, isobutanol, 2-methoxyethanol or the like), dimethyl sulfoxide, sulfolane or the like. The reaction temperature is normally 20 to 180°C, preferably 50 to 150°C. The amount of thiourea to be used is 1 to 2 mol per 1 mol of the compound (II). In this reaction, hydrogen bromide is generated as a by-product as the reaction proceeds. Then, the reaction can be carried out in the presence of a deacidification agent such as sodium acetate, potassium acetate or the like to trap the hydrogen bromide. The deacidification agent is normally used 1 to 1.5 mol per 1 mol of the compound (II). The compound (III) is produced by this reaction. The compound (III) can optionally be isolated, but it can be used without isolation in the next acid hydrolysis step.


Hydrolysis of the compound (III) is normally carried out in a suitable solvent in the presence of water

and a mineral acid. Examples of the solvent include the solvents used in the reaction of the compound (II) with thiourea. Examples of the mineral acid include hydrochloric acid, hydrobromic acid, sulfuric acid and the like. The amount of the mineral acid to be used is 0.1 to 20 mol, preferably 0.2 to 10 mol per 1 mol of the compound (III). The water is normally added in large excess. This reaction is normally carried out under warming or heating. The reaction temperature is normally 60 to 150°C. The heating time is normally several hours to twenty and several hours.

(2) Production of the compound (I) wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CO}-$

This compound (I-2) can be produced by according to the Scheme 2.

Scheme 2




The oxidation can be carried out according to a known method. Examples thereof include oxidation with manganese dioxide, oxidation with chromic acid (e.g., chromium (IV) oxide-pyridine complex), oxidation with dimethyl sulfoxide and the like [see Shin Jikken Kagaku Koza, Vol. 15 (I-1), (I-2), edited by Japan Chemical Society, Maruzen Shuppan, 1976].

For example, in the case of the oxidation with dimethyl sulfoxide, the oxidation is normally carried out in an inert solvent such as chloroform, dichloromethane, benzene, toluene or the like. Dimethyl sulfoxide may be used as the solvent. The oxidation is carried out in the presence of an electrophilic reagent such as acetic anhydride, phosphoric anhydride, dicyclocarbodiimide, chlorine or the like. The reaction is normally carried out at about -100 to +60°C. The reaction time is about 0.5 to 50 hours.


- (3) Production of the compound (I) wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CH}(\text{OR})-$  and R is other than a hydrogen atom

This compound (I-3) can be produced according to the Scheme 3.

Scheme 3



(I-1)



(I-3)

This acylation is normally carried out by reacting the compound (I-1) with an acylating agent in a suitable solvent in the presence of a base. Examples of the solvent include esters such as ethyl acetate and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane and the like, ketones such as acetone, methyl ethyl ketone and the like, chlorinated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like, dimethylformamide and the like. Examples of the acylating agent include formic acid and acid anhydrides and acid halides derived from aliphatic, aryl aliphatic and aromatic carboxylic acids. Examples of


the aliphatic carboxylic acid include those having 2 to 6 carbon atoms such as acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, hexanoic acid and the like. Examples of the aryl aliphatic carboxylic acid include those having 8 to 9 carbon atoms such as phenylacetic acid, phenylpropionic acid and the like. Examples of the aromatic carboxylic acid include those having 7 to 8 carbon atoms such as benzoic acid and the like. These aromatic ring can be substituted by one or more substituents such as halogen atom (fluorine, chlorine, bromine or the like), lower alkoxy having 1 to 4 carbon atoms (e.g., methoxy, ethoxy or the like), trifluoromethyl or the like.

The amount of the acylating agent to be used is normally 1 to 10 mol, preferably 1 to 2 mol per 1 mol of the compound (I-1). Examples of the base include amines such as pyridine, triethylamine and the like, carbonates and bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate and the like. The base to be used is normally equal or in large excess based on the acylating agent. When pyridine is used as the base, the pyridine in large excess can also be used as the solvent. The reaction is carried out at  $-20$  to  $+40^{\circ}\text{C}$ . The reaction time is normally 10 minutes to 24 hours.

- (4) Production of the compound (I) wherein X is  $-\text{CH}_2-$  and Q is  $-\text{CH}_2\text{COOH}$

This compound (I-4) can be produced according to the Scheme 4.

Scheme 4




wherein Y is as defined above.

The reaction of the compound (IV) with thiourea can be carried out according to the same manner as that described with respect to the reaction of the compound (II) with thiourea to obtain the compound (V). The acid hydrolysis of the compound (V) can be carried out according to the same manner as that described with respect to the hydrolysis of the compound (III).

- (5) Production of the compound (I) wherein X is  $-\text{CO}-$  and Q is  $\text{CH}_3\text{CH}_2-$

This compound (I-5) can be produced according to the Scheme 5.

Scheme 5




The oxidation can be carried out according to the same manner as that described with respect to the oxidation of the compound (I-1) to the compound (I-2).

The compound (I), its salt or stereoisomeric form thus obtained can be isolated and purified by known separation and purification techniques such as concentration, concentration under reduced pressure, crystallization, recrystallization, dissolution in a different solvent, chromatography or the like.

The starting material (II) can be produced according to the Scheme 6.

Scheme 6






wherein Y is as defined above.

Conversion of the compound (VI) into the compound (VII) is carried out by reacting the compound (VI) with chloromethyl methyl ether in the presence of sodium hydride, sodium hydroxide, potassium hydroxide or the like. The reaction can be carried out in a solvent such as dimethylformamide, dimethyl sulfoxide, tetrahydrofuran or the like at -20 to +60°C. Then, the compound (VII) is reacted with formalin at 100 to 180°C to produce the compound (VIII). Conversion of the compound (VIII) into the compound (IX) is carried out by reacting the compound (VIII) with 4-fluoronitrobenzene in the presence of sodium hydride, sodium hydroxide, potassium hydroxide or the like. The reaction can be carried out in a solvent such as dimethylformamide, dimethyl sulfoxide, tetrahydrofuran or the like at -20 to +60°C. Catalytic hydrogenation of the compound (IX) is carried out, for example, by using palladium on carbon as a catalyst according to a conventional manner to obtain the compound (X). Conversion of the compound (X) into the compound (XI) is carried out by subjecting the compound (X) to diazotization in the presence of a hydrogen halide followed by so-called Meerwein arylation wherein the diazo compound is reacted with acrylic acid or its esters in the presence of a copper catalyst (e.g., cuprous oxide, cupric oxide, cuprous chloride, cupric chloride, cuprous bromide, cupric bromide, etc.).

- 16 -

The compound (IV) can be produced according to the Scheme 7.

Scheme 7



- 18 -

In this process, the compound (XV) prepared according to the same manner as that described with respect to the production of compound (IX) is reacted with an acid to obtain the compound (XVI). This reaction can be carried out in the presence of an acid such as hydrochloric acid, sulfuric acid or the like in a solvent containing water at 0 to 100°C. The compound (XVI) is chlorinated with thionyl chloride to obtain the compound (XVII). The compound (XVII) is reacted with potassium cyanide (or sodium cyanide) in a solvent such as acetone, dioxane, N,N-dimethylformamide, dimethylsulfoxide or the like at 0 to 100°C to obtain the compound (XVIII). The compound (XVIII) is subjected to catalytic reduction according to the same manner as that described with respect to the compound (IX) to obtain the compound (IV).

The starting material of the above Scheme 5 is known and disclosed in U.S. Patent No. 4,582,839.

The following Experiment shows that the compound (I) of the present invention has excellent hypoglycemic and hypolipidemic activities.

#### Experiment

Hypoglycemic and hypolipidemic activities  
in mice

Test compounds were mixed with laboratory chow diet (CE-2, Clea Japan Inc., Tokyo, Japan) in a proportion of 0.005% by weight. The dietary admixture was given freely to

KKAY-mice (male, 9 to 10 weeks old) for 4 days. During the period, water was given freely. Blood was collected from the orbital venous plexus. The blood sugar level was determined according to glucose oxidase method. The plasma lipid level was enzymatically determined by using Kit Cleantech TG-S (Iatron, Tokyo, Japan). The results are shown in Table 1. Values represent % reduction from control groups.

Table 1

Compound (Example No.)	Hypoglycemic activity (%)	Hypolipidemic activity (%)
1	46	5
2	56	43

As is clear from Table 1, the compound (I) of the present invention has excellent hypoglycemic and hypolipidemic activities, and is useful for a therapeutic agent for treating diabetes, hyperlipidemia and the like.

Further, the compound (I) of the present invention causes neither lactic acidosis nor serious hypoglycemia.

As described hereinabove, according to the present invention, there is provided novel thiazolidinedione derivatives or salts thereof which have excellent hypoglycemic and hypolipidemic activities without causing lactic acidosis and hypoglycemia.

- 20 -

The following Examples and Reference Examples further illustrates the present invention in detail but are not to be construed to limit the scope of the invention.

Example 1

A mixture of methyl 2-bromo-3-[4-[2-[5-(1-methoxymethoxyethyl)-2-pyridyl]ethoxy]phenyl]propionate (27.0 g), thiourea (4.6 g), sodium acetate (4.9 g) and ethanol (250 ml) was heated under reflux for 4 hours. To the reaction mixture was added 2N hydrochloric acid (250 ml). The mixture was further heated under reflux for 20 hours and concentrated under reduced pressure. The residue was neutralized with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The oily residue thus obtained was subjected to silica gel column chromatography. A fraction eluted with chloroform-methanol (40:1, v/v) gave 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione (14.8 g, yield: 66%). This crude compound was recrystallized from ethanol to obtain colorless prisms, m.p. 155-156°C.

Elemental Analysis for  $C_{19}H_{20}N_2O_4S \cdot 1/4C_2H_5OH$ ,

Calcd.: C, 61.00; H, 5.64; N, 7.30

Found : C, 60.87; H, 5.70; N, 7.31

Example 2

Acetic anhydride (25 ml) was added to a solution of 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione (8.7 g) in dimethyl sulfoxide (100 ml). The mixture was allowed to stand at room temperature for 4 days. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The oily residue was subjected to silica gel column chromatography. A fraction eluted with chloroform-methanol (100:1, v/v) gave 5-[4-[2-(5-acetyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione. This compound was recrystallized from ethanol to obtain colorless prisms, m.p. 114-115°C.

Elemental Analysis for  $C_{19}H_{18}N_2O_4S \cdot 1/4C_2H_5OH$ ,

Calcd.: C, 61.32; H, 5.15; N, 7.33

Found : C, 61.40; H, 5.08; N, 7.43

Example 3

5-[4-[2-[5-(1-Hydroxyethyl)-2-pyridyl]ethoxy]-benzyl]-2,4-thiazolidinedione (0.3 g) was dissolved in hydrogen chloride-ethanol (25%, 1 ml). The solution was stirred at room temperature for 30 minutes and precipitated crystals were filtered off. The crystals were recrystallized from ethanol to obtain 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride (0.21 g, yield: 62 %) as colorless prisms,

- 22 -

m.p. 212-213°C.

Elemental Analysis for  $C_{19}H_{20}N_2O_4S \cdot HCl$

$\cdot 1/4 C_2H_5OH$ ,

Calcd.: C, 55.71; H, 5.39; N, 6.66

Found : C, 55.75; H, 5.36; N, 6.77

Example 4

A mixture of 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]benzyl]-2,4-thiazolidinedione  $\cdot 1/4$  ethanol (384 mg), acetic anhydride (0.5 ml) and pyridine (5 ml) was stirred at room temperature for 12 hours. After addition of water (5 ml), the mixture was concentrated under reduced pressure and the remaining crystals were filtered off. The crystals were recrystallized from ethyl acetate-hexane to obtain 5-[4-[2-[5-(1-acetoxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione (345 mg, yield: 83%) as colorless prisms, m.p. 143-144°C.

Elemental Analysis for  $C_{21}H_{22}N_2O_5S$ ,

Calcd.: C, 60.85; H, 5.35; N, 6.76

Found : C, 60.73; H, 5.45; N, 6.79

Example 5

A mixture of 5-[4-[2-(5-cyanomethyl-2-pyridyl)ethoxy]benzyl]-2-imino-4-thiazolidinone (2.3 g) and 4N hydrochloric acid (100 ml) was heated under reflux for 24 hours and concentrated under reduced pressure. The residue was neutralized with saturated aqueous solution of sodium bicarbonate and acidified with addition of acetic acid.



- 23 -

Crystals precipitated were filtered off and dissolved in ethyl acetate (200 ml)-methanol (200 ml). The resulting solution was washed with water and dried over magnesium sulfate and the solvent was distilled off to obtain 5-[4-[2-(5-carboxymethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (1.9 g, yield: 79%). This compound was recrystallized from ethanol to obtain colorless prisms, m.p. 144-145°C.

Elemental Analysis for  $C_{19}H_{18}N_2O_5S$ ,

Calcd.: C, 59.06, H, 4.70; N, 7.25

Found : C, 58.89; H, 4.69; N, 7.08

#### Example 6

A mixture of 5-[4-[2-(5-ethyl-2-pyridyl)-2-hydroxyethoxy]benzyl]-2,4-thiazolidinedione  $\cdot 1/2$   $C_2H_5OH$  (396 mg), acetic anhydride (1.5 ml) and dimethylsulfoxide (4 ml) was stirred at room temperature for 5 hours and then poured into water. The mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with water and dried over magnesium sulfate and the solvent was distilled off. The oily residue was subjected to silica gel chromatography. A fraction eluted with chloroform-methanol (100:1, v/v) gave 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-2,4-thiazolidinedione (75 mg, yield: 20%). This was recrystallized from ethyl acetate-hexane to obtain colorless prisms, m.p. 148-149°C.

- 24 -

Elemental Analysis for  $C_{19}H_{18}N_2O_4S$ ,

Calcd.: C, 61.61; H, 4.90; N, 7.56

Found : C, 61.39; H, 4.91; N, 7.37

Example 7

Preparation of tablets

Tablets are prepared according to the following formulation.

(1)	5-[4-[2-[5-(1-hydroxyethyl)- 2-pyridyl]ethoxy]benzyl]-2,4- thiazolidinedione 1/4 ethanol solvate	100 g
(2)	Lactose	50 g
(3)	Corn starch	15 g
(4)	Calcium carboxymethylcellulose	44 g
(5)	Magnesium stearate	1 g
	1000 tablets	210 g

All the ingredients of (1), (2) and (3), and 30 g of the ingredient (4) were kneaded with water. The mixture was dried under vacuum and then granulated. The granules were mixed with 14 g of the ingredient (4) and 1 g of the ingredient (5). The resulting mixture was compressed into tablets by a tablet machine to produce 1000 tablets of 8 mm in diameter containing 100 mg of the ingredient (1) per tablet.

Reference Example 1

Sodium hydride in oil (60%, 7.0 g) was added with

- 25 -

ice-cooling to a solution of 5-(1-hydroxyethyl)-2-methylpyridine (20.0 g) in N,N-dimethylformamide (120 ml). The mixture was stirred for 15 minutes. Then, chloromethyl methyl ether (14.1 g) was added dropwise at the same temperature. The reaction mixture was further stirred for 30 minutes with ice-cooling. The mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate and subjected to distillation under reduced pressure to obtain 5-(1-methoxymethoxyethyl)-2-methylpyridine (21.5 g, yield: 81 %), b.p. 78-80°C/0.8 mmHg.

#### Reference Example 2

The mixture of 5-(1-methoxymethoxyethyl)-2-methylpyridine (21.0 g) and formalin (37% aq. HCHO, 14.1 g) was heated at 150 to 160°C for 8 hours in a sealed tube. The reaction mixture was concentrated under reduced pressure and then the residue was subjected to silica gel column chromatography. A fraction eluted with chloroform-methanol (25:1, v/v) gave 2-[5-(1-methoxymethoxyethyl)-2-pyridyl]ethanol (7.8 g, yield: 32 %) as oil.

NMR ( $\delta$  ppm in CDCl<sub>3</sub>): 1.49 (3H, d, J=7Hz), 3.01 (2H, t, J=6Hz), 3.36 (3H, s), 4.03 (2H, t, J=6Hz), 4.53 (1H, d, J=7Hz), 4.61 (1H, d, J=7Hz), 4.77 (1H, d, J=7Hz), 7.15 (1H, d, J=8Hz), 7.62 (1H, dd, J=8 and 2Hz), 8.46 (1H, d, J=2Hz).

Reference Example 3

Sodium hydride in oil (60%, 1.6 g) was added in small portions with ice-cooling to a solution of 2-[5-(1-methoxymethoxyethyl)-2-pyridyl]ethanol (7.5 g) and 4-fluoronitrobenzene (5.0 g) in N,N-dimethylformamide (50 ml). The reaction mixture was stirred with ice-cooling for additional 1 hour, poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The oily residue was subjected to silica gel column chromatography. A fraction eluted with chloroform-methanol (40:1, v/v) gave 5-(1-methoxymethoxyethyl)-2-[2-(4-nitrophenoxy)ethyl]pyridine (8.4 g, yield: 71 %) as oil.

NMR ( $\delta$  ppm in  $\text{CDCl}_3$ ): 1.49 (3H, d,  $J=7\text{Hz}$ ), 3.30 (2H, t,  $J=6\text{Hz}$ ), 3.36 (3H, s), 4.48 (2H, t,  $J=6\text{Hz}$ ), 4.52 (1H, d,  $J=7\text{Hz}$ ), 4.62 (1H, d,  $J=7\text{Hz}$ ), 4.79 (1H, d,  $J=7\text{Hz}$ ), 6.97 (2H, d,  $J=9\text{Hz}$ ), 7.25 (1H, d,  $J=8\text{Hz}$ ), 7.64 (1H, dd,  $J=8$  and 2 Hz), 8.18 (2H, d,  $J=9\text{Hz}$ ), 8.53 (1H, d,  $J=2\text{Hz}$ ).

Reference Example 4

A mixture of 5-(1-methoxymethoxyethyl)-2-[2-(4-nitrophenoxy)ethyl]pyridine (8.2 g), 5% palladium-carbon (50% wet, 0.8 g) and ethyl acetate (100 ml) was subjected to catalytic reduction at room temperature and at the pressure of 1 atm. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The oily residue

- 27 -

was dissolved in acetone (80 ml)-hydrobromic acid (47%, 16.9 g). A solution of sodium nitrite (1.9 g) in water (5 ml) was added dropwise at 0 to 5°C. The reaction mixture was stirred at 5°C for additional 20 minutes. Then, methyl acrylate (12.7 g) was added thereto and the resulting mixture was warmed to 37°C. While this mixture was stirred vigorously, cuprous oxide (0.3 g) was added in small portions to the mixture. After the evolution of nitrogen gas had ceased, the reaction mixture was concentrated under reduced pressure. The residue was made basic with conc.  $\text{NH}_4\text{OH}$  and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The oily residue was subjected to silica gel column chromatography. A fraction eluted with ether-hexane-triethylamine (25:25:1, v/v) gave methyl 2-bromo-3-[4-[2-[5-(1-methoxymethoxyethyl)-2-pyridyl]ethoxy]phenyl]propionate (5.6 g, yield: 50 %) as oil.

NMR ( $\delta$  ppm in  $\text{CDCl}_3$ ): 1.48 (3H, d,  $J=7\text{Hz}$ ), 3.1-3.4 (2H, m), 3.24 (2H, t,  $J=6\text{Hz}$ ), 3.36 (3H, s), 3.71 (3H, s), 4.33 (2H, t,  $J=6\text{Hz}$ ), 4.53 (1H, d,  $J=7\text{Hz}$ ), 4.61 (1H, d,  $J=7\text{Hz}$ ), 4.5-4.7 (1H, m), 4.77 (1H, q,  $J=6\text{Hz}$ ), 6.83 (2H, d,  $J=9\text{Hz}$ ), 7.09 (2H, d,  $J=9\text{Hz}$ ), 7.245 (1H, d,  $J=8\text{Hz}$ ), 7.61 (1H, dd,  $J=8$  and  $2\text{ Hz}$ ), 8.50 (1H, d,  $J=2\text{Hz}$ ).

#### Reference Example 5

A solution of methyl 6-methylnicotinate (45.4 g) in

- 28 -

tetrahydrofuran (50 ml) was added dropwise to a suspension of lithium aluminium hydride ( $\text{LiAlH}_4$ , 5.7 g) in tetrahydrofuran (250 ml) at room temperature. The mixture was stirred at room temperature for additional 1 hour and water (30 ml) was added dropwise with ice-cooling. Insoluble materials were filtered off and the filtrate was concentrated. The residue was distilled under reduced pressure to obtain 6-methyl-3-pyridylmethanol (31 g, yield: 84 %), b.p. 98-100°C/0.5 mmHg.

#### Reference Example 6

6-Methyl-3-pyridylmethanol (30.8 g) was dissolved in tetrahydrofuran (200 ml) and sodium hydride in oil (60%, 11 g) was added thereto. The mixture was stirred with ice-cooling for 30 minutes. Then, chloromethyl methyl ether (22.1 g) was added dropwise with ice-cooling and the mixture was stirred for additional 1 hour. The mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water and dried over magnesium sulfate and the solvent was distilled off under reduced pressure to obtain 5-methoxymethoxymethyl-2-methylpyridine (31 g, yield: 74%), b.p. 85-87°C/0.5 mmHg.

#### Reference Example 7

A mixture of 5-methoxymethoxymethyl-2-methylpyridine (30.5 g) and formalin (37% aq.,  $\text{HCHO}$ , 22.2 g) was heated in a sealed tube at 150 to 160°C for 8 hours. The reaction mixture was concentrated under reduced pressure

and the oily residue was subjected to silica gel column chromatography. A fraction eluted with chloroform-methanol (20:1, v/v) gave 2-(5-methoxymethoxymethyl-2-pyridyl)ethanol (11.8 g, yield: 33%) as oil.

NMR ( $\delta$  ppm in  $\text{CDCl}_3$ ): 3.02 (2H, t,  $J=6\text{Hz}$ ), 3.41 (3H, s), 4.02 (2H, t,  $J=6\text{Hz}$ ), 4.59 (2H, s), 4.71 (2H, s), 7.16 (1H, d,  $J=8\text{Hz}$ ), 7.64 (1H, dd,  $J=8$  and  $2\text{Hz}$ ), 8.48 (1H, d,  $J=2\text{Hz}$ ).

#### Reference Example 8

To a solution of 2-(5-methoxymethoxymethyl-2-pyridyl)ethanol (11.6 g) and 4-fluoronitrobenzene (8.5 g) in  $N,N$ -dimethylformamide (100 ml) was added by portions sodium hydride in oil (60%, 2.8 g) with ice-cooling. The reaction mixture was stirred with ice-cooling for additional 1 hour, poured into water and then extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The oily residue was subjected to silica gel column chromatography. A fraction eluted with chloroform-methanol (40:1, v/v) gave 5-methoxymethoxymethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (14.7 g, yield: 79%) as oil.

NMR ( $\delta$  ppm in  $\text{CDCl}_3$ ): 3.30 (2H, t,  $J=6\text{Hz}$ ), 3.41 (3H, s), 4.47 (2H, t,  $J=6\text{Hz}$ ), 4.60 (2H, s), 4.71 (2H, s), 6.94 (2H, d,  $J=9\text{Hz}$ ), 7.26 (1H, d,  $J=8\text{Hz}$ ), 7.66 (1H, dd,  $J=8$  and  $2\text{Hz}$ ), 8.17 (2H, d,  $J=9\text{Hz}$ ), 8.54 (1H, d,  $J=2\text{Hz}$ ).

Reference Example 9

A mixture of 5-methoxymethoxymethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (14.5 g), 2N hydrochloric acid (50 ml) and methanol (50 ml) was stirred under reflux for 2 hours. The reaction mixture was concentrated and the residue was neutralized with saturated aqueous solution of sodium bicarbonate and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over magnesium sulfate and concentrated under reduced pressure to obtain 5-hydroxymethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (9.7 g, yield: 88%). This compound was recrystallized from ethyl acetate to obtain colorless prisms, m.p. 144-145°C.

Elemental Analysis for  $C_{14}H_{14}N_2O_4$ ,

Calcd.: C, 61.31; H, 5.14; N, 10.21

Found : C, 61.01; H, 5.14; N, 10.13.

Reference Example 10

To a solution of 5-hydroxymethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (9.4 g) in chloroform (100 ml) was added thionyl chloride (7.0 g) and the mixture was stirred under reflux for 30 minutes. After cooling, the reaction mixture was washed with saturated aqueous solution of sodium bicarbonate and then water, dried over magnesium sulfate and concentrated under reduced pressure to obtain 5-chloromethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (9.7 g, yield: 85%). The compound was recrystallized from ethyl acetate-hexane to obtain colorless needles, m.p. 77-78°C.



Elemental Analysis for  $C_{14}H_{13}N_2O_3Cl$ ,

Calcd.: C, 57.44; H, 4.48; N, 9.57

Found : C, 57.07, H, 4.42; N, 9.46.

Reference Example 11

A mixture of 5-chloromethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (9.5 g), potassium cyanide (3.2 g) and N,N-dimethylformamide (100 ml) was stirred at 60°C for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over magnesium sulfate and concentrated under reduced pressure to obtain 5-cyanomethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (9.0 g, yield: 98%). This compound was recrystallized from ethyl acetate-hexane to obtain colorless prisms, m.p. 94-95°C.

Elemental Analysis for  $C_{15}H_{13}N_3O_3$ ,

Calcd.: C, 63.60; H, 4.63; N, 14.83

Found : C, 63.19; H, 4.63; N, 14.41.

Reference Example 12

A mixture of 5-cyanomethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine (8.8 g), 5% palladium-carbon (50% wet, 1.0 g) and ethyl acetate (100 ml) was subjected to catalytic reduction at room temperature and at the pressure of 1 atm. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The oily residue was dissolved in acetone (80 ml)-hydrobromic acid (47%, 21.4 g). To the solution was added dropwise a solution of sodium

- 32 -

nitrite (2.4 g) in water (5 ml) at 0 to 5°C. The reaction mixture was stirred at 5°C for additional 20 minutes and methyl acrylate (16.1 g) was added thereto. The mixture was warmed to 37°C and cuprous oxide (0.3 g) was added in small portions, while the mixture was vigorously stirred. After the evolution of nitrogen gas had ceased, the reaction mixture was concentrated under reduced pressure and the residue was made basic with conc.  $\text{NH}_4\text{OH}$  and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The oily residue was subjected to silica gel column chromatography. A fraction eluted with ether-hexane-triethylamine (25:25:1, v/v) gave methyl 2-bromo-3-[4-[2-(5-cyanomethyl-2-pyridyl)ethoxy]-phenyl]propionate (7.3 g, yield: 58%) as oil.

NMR ( $\delta$  ppm,  $\text{CDCl}_3$ ): 3.1-3.4 (2H, m), 3.26 (2H, t,  $J=6\text{Hz}$ ), 3.71 (2H, s), 3.74 (3H, s), 4.3-4.4 (1H, m), 4.33 (2H, t,  $J=6\text{Hz}$ ), 6.76 (2H, d,  $J=9\text{Hz}$ ), 7.2-7.4 (3H, m), 7.65 (1H, dd,  $J=8$  and  $2\text{Hz}$ ), 8.50 (1H, d,  $J=2\text{Hz}$ ).

#### Reference Example 13

A mixture of methyl 2-bromo-3-[4-[2-(5-cyanomethyl-2-pyridyl)ethoxy]phenyl]propionate (7.2 g), thiourea (1.2 g), sodium acetate (1.3 g) and ethanol (80 ml) was heated under reflux for 5 hours and concentrated under reduced pressure. To the residue was added saturated aqueous sodium bicarbonate solution (100 ml)-ether (50 ml) and the mixture

- 33 -

was stirred for 15 minutes. The precipitated crystals were filtered off to obtain 5-[4-[2-(5-cyanomethyl-2-pyridyl)ethoxy]benzyl]-2-imino-4-thiazolidinone (2.5 g, yield: 38%). This compound was recrystallized from chloroform-methanol to obtain colorless prisms, m.p. 211-212°C.


Elemental Analysis for  $C_{19}H_{18}N_4O_2S$ ,

Calcd.: C, 62.28; H, 4.95; N, 15.29

Found : C, 62.21; H, 4.89; N, 15.15.

What is claimed is:

1. A thiazolidinedione derivative of the general formula (I):



wherein X is  $-\text{CH}_2-$  or  $-\text{CO}-$ , Q is  $\text{CH}_3\text{CO}-$ ,  $\text{CH}_3\text{CH}(\text{OR})-$  or  $-\text{CH}_2\text{COOH}$ , when X is  $-\text{CH}_2-$ , wherein R is a hydrogen atom or an acyl group, or Q is  $\text{CH}_3\text{CH}_2-$ , when X is  $-\text{CO}-$ , a pharmaceutically acceptable salt thereof, or a pure stereoisomeric form thereof.

2. A thiazolidinedione derivative according to claim 1, wherein X is  $-\text{CH}_2-$  or  $-\text{CO}-$ , Q is  $\text{CH}_3\text{CO}-$  or  $\text{CH}_3\text{CH}(\text{OR})-$ , when X is  $-\text{CH}_2-$ , wherein R is an acyl group, or Q is  $\text{CH}_3\text{CH}_2-$ , when X is  $-\text{CO}-$ .

3. A thiazolidinedione derivative according to claim 1, wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CH}(\text{OH})-$  or  $-\text{CH}_2\text{COOH}$ .

4. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-(5-acetyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

5. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

6. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-acetoxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

7. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-propionyloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

8. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-butyryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

9. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-isobutyryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

10. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-valeryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

11. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-isovaleryloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

12. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-pivaloyloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.

13. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-[5-(1-benzoyloxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione or its salt.


14. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-(5-carboxymethyl-2-

- 36 -

pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione or its salt.


15. The thiazolidinedione derivative according to claim 1 which is 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-2,4-thiazolidinedione or its salt.

16. A process for producing a thiazolidinedione derivative of the general formula (I):




wherein X is  $-\text{CH}_2-$  or  $-\text{CO}-$ , Q is  $\text{CH}_3\text{CO}-$ ,  $\text{CH}_3\text{CH}(\text{OR})-$  or  $-\text{CH}_2\text{COOH}$ , when X is  $-\text{CH}_2-$ , wherein R is a hydrogen atom or an acyl group, or Q is  $\text{CH}_3\text{CH}_2-$ , when X is  $-\text{CO}-$ , a pharmaceutically acceptable salt thereof, or a pure stereoisomeric form thereof, which comprises steps of:

(a) for the production of the derivative of the general formula (I) wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CH}(\text{OH})-$ , reacting a compound of the formula (II):



wherein  $\text{R}^1$  is a hydrogen atom or a lower alkyl, and Y is a leaving group, with thiourea and then subjecting the

resulting compound of the formula (III)




to acid hydrolysis; or

(b) for the production of the derivative of the general formula (I) wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CO}-$ , oxidizing the derivative of the general formula (I) wherein Q is  $\text{CH}_3\text{CH}(\text{OH})-$ ; or

(c) for the production of the derivative of the general formula (I) wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CH}(\text{OR})-$  and R is other than a hydrogen atom, acylating the derivative of the general formula (I) wherein Q is  $\text{CH}_3\text{CH}(\text{OH})-$ ; or


(d) for the production of the derivative of the general formula (I) wherein X is  $-\text{CH}_2-$  and Q is  $-\text{CH}_2\text{COOH}$ , subjecting a compound of the formula (V):



to acid hydrolysis;

- 38 -

(e) for the production of the derivative of the general formula (I) wherein X is -CO- and Q is  $\text{CH}_3\text{CH}_2-$ , oxidizing a compound of the formula



and then optionally converting the resulting derivative into its salt.

17. A method according to claim 16, wherein the desired compound is a thiazolidinedione derivative wherein X is  $-\text{CH}_2-$  or  $-\text{CO}-$ , Q is  $\text{CH}_3\text{CO}-$  or  $\text{CH}_3\text{CH}(\text{OR})-$ , when X is  $-\text{CH}_2-$ , wherein R is an acyl group, or Q is  $\text{CH}_3\text{CH}_2-$ , when X is  $-\text{CO}-$ .

18. A method according to claim 16, wherein the desired compound is a thiazolidinedione derivative wherein X is  $-\text{CH}_2-$  and Q is  $\text{CH}_3\text{CH}(\text{OH})-$  or  $-\text{CH}_2\text{COOH}$ .

19. A pharmaceutical composition for treating diabetes comprising the thiazolidinedione derivative according to claim 1, and a pharmacologically acceptable carrier, excipient or diluent.

20. A pharmaceutical composition for treating diabetes comprising the thiazolidinedione derivative according to claim 2, and a pharmacologically acceptable carrier, excipient or diluent.



21. A pharmaceutical composition for treating diabetes comprising the thiazolidinedione derivative according to claim 3, and a pharmacologically acceptable carrier, excipient or diluent.

22. A method for treating diabetes which comprising administering an effective amount of the thiazolidinedione derivative according to claim 1, optionally together with a pharmacologically acceptable carrier, excipient or diluent to a patient requiring such a treatment.

23. A method for treating diabetes which comprising administering an effective amount of the thiazolidinedione derivatives according to claim 2, optionally together with a pharmacologically acceptable carrier, excipient or diluent to a patient requiring such a treatment.

24. A method for treating diabetes which comprising administering an effective amount of the thiazolidinedione derivatives according to claim 3, optionally together with a pharmacologically acceptable carrier, excipient or diluent to a patient requiring such a treatment.

25. Use of the thiazolidinedione derivative according to claim 1, in the preparation of a pharmaceutical composition for treating diabetes.

26. Use of the thiazolidinedione derivative according to claim 2, in the preparation of a pharmaceutical composition for treating diabetes.

27. Use of the thiazolidinedione derivative according to claim 3, in the preparation of a pharmaceutical composition for treating diabetes.

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5                      C 07 D 417/12                      A 61 K 31/44		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1.5	C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>o</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0193256 (TAKEDA) 3 September 1986, see claims ---	1-3, 19- 27
X	Chemical and Pharmaceutical Bulletin, vol. 30, no. 10, October 1982, (Tokyo, JP), T. SOHDA et al.: "Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidi ne-2,4-dione (ADD-3878) and its derivatives", pages 3580-3600, see pages 3585-3589 ---	1-3, 19- 27
X	EP,A,0008203 (TAKEDA) 20 February 1980, see claims; pages 1,13,19,20, examples 37-42 -----	1-3, 19- 27
<p><sup>o</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
29-07-1992	17. 09. 92	
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer Wolfgang Weinberg	

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 22-24 are directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9202566

SA 59198

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 01/09/92  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0193256	03-09-86	JP-A- 61267580	27-11-86
EP-A- 0008203	20-02-80	JP-C- 1433701	07-04-88
		JP-A- 55022636	18-02-80
		JP-B- 62042903	10-09-87
		CA-A- 1131644	14-09-82
		US-A- 4287200	01-09-81
		US-A- 4340605	20-07-82
		US-A- 4438141	20-03-84
		US-A- 4444779	24-04-84